linjc16/ctgov huggingface dataset:
Exercise Training Programm for Physiotherapy Students

Study Overview
=================
Brief Summary
-----------------
In this study, i.e. randomized controlled trial, the effect of an exercise training program on mental and anatomical characteristics of physiotherapy students is measured.

Official Title
-----------------
Effect of an Exercise Training Programm on Mental and Anatomical Characteristics of Physiotherapy Students - a Randomized Controlled Trial

Conditions
-----------------
Healthy, Student, Physical Therapy

Intervention / Treatment
-----------------
* Other: Exercise Training Program


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age ≥18 signed consent THIM student good health status Exclusion Criteria: alcohol drugs smoking

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Exercise Training Program<br> | Other: Exercise Training Program<br>* 10min of coordination and strength training (2-3x per week) during 2-6 weeks<br>|
| No Intervention: Control<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| d2-R-Test | Mental | Change from baseline attention and concentration at 4 weeks (objective) | 
| AKA-Questionnaire (attention, concentration, learning ability) | Participants fill out a questionnaire about attention, concentration and learning ability. There are five possible answers for each item from 1 (completely disagree) to 5 (completely agree). | Change from baseline attention and concentration at 4 weeks (subjective) | 
| M360 - physiological parameter of the spine | Participants are measured in different positions (upright, flexion, extension; measured in degrees) to assess position, stability and mobility of the spine. The M360 will be guided along the back and the data will be collected electronically (https://www.idiag.ch/idiag-m360/). | Change from baseline position and mobility of the spine at 4 weeks | 
| Pain (Visual Analogue Scale) | Participants can use this scale to classify their pain from No pain and Maximum pain imaginable by means of a slider. | Change from baseline pain (back) at 4 weeks | 
| FAW-Questionnaire (Actual physical well-being) | Participants fill out a questionnaire with 58 questions. Each question has five possible answers from 0 (completely disagree) to 4 (completely agree). The highter the score the better the actual physical well-being. | Change from baseline physical well-being at 4 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
exercise, anatomical, mental, training program
The Use of Ultra Rice Compared to Iron Drops Consumed by Anemic Children

Study Overview
=================
Brief Summary
-----------------
Background: How best to improve iron status among infants in low-income settings is of continued concern in many countries, including Brazil Objective: Design: In a double blind, 5-mo, home-based trial in Brazil, mildly anemic 6 - 24 month-old children (n=175) were randomly assigned to receive either Ultra Rice (URG) fortified with 23,4, mg Fe as micronized ferric pyrophosphate (MFP) and a placebo solution of iron drops, or identical non-fortified rice (CG) and a solution of iron drops. Parents were instructed on the correct dosage of iron drops and to feed their children (including whether and how much rice) as they normally would. Iron status and hemoglobin (Hb) were measured at baseline and at 5 mo.

Official Title
-----------------
Efficacy of Iron Fortified Ultra Rice Compared to Supplemental Iron Drops in Infants and Young Children

Conditions
-----------------
Anemia, Iron Deficiency Anemia

Intervention / Treatment
-----------------
* Dietary Supplement: iron fortified rice
* Dietary Supplement: iron drops


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: anemia Exclusion Criteria: non anemic

Ages Eligible for Study
-----------------
Minimum Age: 6 Months
Maximum Age: 24 Months

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: iron fortified rice group<br> | Dietary Supplement: iron fortified rice<br> <br> |
| Placebo Comparator: iron drop group<br> | Dietary Supplement: iron drops<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Before, the prevalence of ID and anemia in sample were 73.1% and 100%, respectively. At 5-mo, increases occurred in serum ferritin (SF) and hemoglobin (Hb). SF and Hb were observed in both groups. Increases in both measures were seen in the URG group. |  | Before and after 5 months |
Intraoperative Laser Speckle Contrast Imaging of Cerebral Blood Flow

Study Overview
=================
Brief Summary
-----------------
The purpose of this research study is to evaluate the ability of laser speckle contrast imaging to visualize blood flow in real time during neurosurgery. Real-time blood flow visualization during surgery could help neurosurgeons better understand the consequences of vascular occlusion events during surgery, recognize potential adverse complications, and thus prompt timely intervention to reduce the risk of stroke. The current standard for visualizing cerebral blood flow during surgery is indocyanine green angiography (ICGA), which involves administering a bolus of fluorescent dye intravenously and imaging the wash-in of the dye to determine which vessels are perfused. Unfortunately, ICGA can only be used a few times during a surgery due to the need to inject a fluorescent dye, and provides only an instantaneous view of perfusion rather than a continuous view. Laser speckle contrast imaging does not require any dyes or tissue contact and has the potential to provide complementary information to ICGA. In this study we plant to collect blood flow images with laser speckle contrast imaging and to compare the images with ICGA that is performed as part of routine care during neurovascular surgical procedures such as aneurysm clipping.

Official Title
-----------------
Intraoperative Laser Speckle Contrast Imaging of Cerebral Blood Flow

Conditions
-----------------
Aneurysm, Brain, Arteriovenous Malformation of Brain, Neurovascular Disorder

Intervention / Treatment
-----------------
* Diagnostic Test: ICGA imaging


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adults (18 years or older). Size of craniotomy at least 2 cm. Possibility of intraoperative ICGA. Able to render written informed consent. Exclusion Criteria: Patients unable to legally consent. Patients with impaired cognitive function.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| neurovascular surgery group<br>Subjects undergoing neurovascular surgery including aneurysm clipping | Diagnostic Test: ICGA imaging<br>* subjects undergoing intraoperative ICGA imaging<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| blood flow visible in laser speckle contrast images | Ability of laser speckle contrast images to reveal blood flow during surgery | during surgical procedure |
Genetic Polymorphism and OROS-Methylphenidate Treatment in Attention Deficit Hyperactivity Disorder(ADHD)

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to examine whether genetic polymorphisms in drug transporters were associated with the side effects of OROS-methylphenidate medication in attention deficit/hyperactivity disorder(ADHD).

Detailed Description
-----------------
20 to 30% of children with attention deficit/hyperactivity disorder(ADHD) do not respond or could not tolerate methylphenidate treatment. Drug transporters such as multidrug resistant proteins(MDR) plays important role in the clearance of psychotropic drugs and their metabolites from brain tissue. It suggested that methylphenidate was a P-glycoprotein(encoded by MDR1 gene)substrate and showed inhibitory effects on the P-glycoprotein efflux function. Single nucleotide polymorphisms(SNP)in the MDR1 gene were analyzed in children and adolescents with OROS-methylphenidate treatment. The hypothesis is that MDR1(ABCB1) polymorphisms are associated with the side effects of OROS-methylphenidate.

Official Title
-----------------
Genetic Polymorphism of Drug Transporters in OROS-Methylphenidate Treatment in Children and Adolescents With Attention Deficit Hyperactivity Disorder(ADHD)

Conditions
-----------------
Attention Deficit Hyperactivity Disorder

Intervention / Treatment
-----------------
* Drug: OROS-methylphenidate (Concerta)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: ADHD Must be able to swallow a capsule Exclusion Criteria: Pervasive developmental disorder Mental retardation Psychotic disorder Bipolar disorder Suicidality Neurological disorder Concurrent psychiatric treatment

Ages Eligible for Study
-----------------
Minimum Age: 6 Years
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: OROS-methylphenidate (Concerta)|dose: 18mg, 27mg, 36mg, 45mg, 54mg/day, po duration: 8 weeks|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Barkley side effects rating scale |  | weeks 1, 2,4,8 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| ADHD rating scale-Korean version; Clinical Global Impressions (CGI) of Severity and Improvement (CGI-S and CGI-I) |  | 8 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Methylphenidate, ADHD, Multidrug resistance(MDR)polymorphism, OROS methylphenidate
Virtual Coach for Mindfulness Meditation Training

Study Overview
=================
Brief Summary
-----------------
Evaluate the effectiveness of using a virtual computer coach to provide mindfulness meditation training, and the coaching support required to initiate a regular practice.

Official Title
-----------------
Virtual Coach for Mindfulness Meditation Training

Conditions
-----------------
Mindfulness Training

Intervention / Treatment
-----------------
* Behavioral: Mindfulness meditation coaching


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: over 18, no previous mindfulness experience, computer literacy Exclusion Criteria: substance abuse, anxiety/depression, psychosis

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Health Services Research
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Mindfulness meditation coaching<br>Assess effectiveness of using a virtual computer coach to train mindfulness meditation | Behavioral: Mindfulness meditation coaching<br>* Participants interact with virtual coach to obtain instruction in mindfulness meditation and coaching support.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Frequency of meditating | Measure the number of times participants meditated per week, throughout the 7 week period of the study. | 7 weeks (weekly) | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
mindfulness, meditation, training, coaching, virtual coach
Procalcitonin as a Marker for the Length of Antibiotic Treatment in Peritonitis and Intra-abdominal Infections

Study Overview
=================
Brief Summary
-----------------
Procalcitonin level used for determining length of antibiotic treatment in peritonitis and intra-abdominal infections. Hypothesis is that length of antibiotic use can be shortened by this method.

Detailed Description
-----------------
Prospective randomized trial

Official Title
-----------------
Etude Prospective Sur l'Impact de l'Utilisation de la Procalcitonine Dans l'évaluation de la Poursuite ou de l'arrêt du Traitement Antibiotique Empirique Lors de péritonites et d'Infections Intra-abdominales

Conditions
-----------------
Secondary or Tertiary Peritonitis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: More than 18 yo Patient requiring surgery for peritonitis or intra-abdominal infection following: perforation, necrosis, previous operation... Mannheim Peritonitis score > 14 SIRS present Probability of survival > 72h Informed consent by patient/relatives Exclusion Criteria: No SIRS Long date corticoid treatment Immunosuppression Thyroid medullary carcinoma Anaphylactic shock Acute hepatic deficiency

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| procalcitonine monitoring<br>PCT group: antibiotic use is tailored by serum procalcitonin values, determined every 48houres. | |
| control group<br>control group: antibiotic use and length of treatment as defined by guidelines | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| antibiotic treatment length, hospitalisation length without antibiotic, infection recurrence, antibiotic cost |  | at one month and during hospital stay |
Safety and Efficacy Pilot Study of AzaSite® (Azithromycin) in Subjects With Blepharitis

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate the safety and efficacy of AzaSite® ophthalmic solution, 1% on signs and symptoms of blepharitis.

Official Title
-----------------
A Multi-Center, Open-Label, Randomized Pilot Study of the Safety and Efficacy of AzaSite® Ophthalmic Solution, 1% in Combination With Mechanical Therapy Versus Mechanical Therapy Alone in Subjects With Blepharitis

Conditions
-----------------
Blepharitis

Intervention / Treatment
-----------------
* Drug: AzaSite®


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: diagnosis of moderate to severe chronic blepharitis if female of childbearing potential, are non-pregnant and non-lactating Exclusion Criteria: had ocular surface surgery (LASIK, refractive, etc.) within the past year unwilling to discontinue the use of contact lenses during the study have glaucoma unable or unwilling to withhold the use of lid scrubs during the study have a serious systemic disease or uncontrolled medical condition that in the judgment of the investigator could confound study assessments or limit compliance currently using any preserved topical ocular medications (with the exception of unpreserved tear substitutes) at the time of entry into the study or during study participation

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br> | Drug: AzaSite®<br>* ophthalmic solution; 1 drop in each eye BID for two days, then 1 drop in each eye QD for  26 days<br>|
| No Intervention: 2<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| change in clinical signs and symptoms associated with blepharitis |  | 4 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| standard ocular safety assessments |  | 4 weeks |
PDA Post NICU Discharge

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to track post-discharge outcomes on prematurely born infants who are discharged from the NICU with a patent ductus arteriosus (PDA). Investigators plan to report on the spontaneous closure rate as well as the incidence of pulmonary and/or cardiac events in these infants. The goal is to identify risk factors associated with adverse outcomes in prematurely born infants who are sent home with a PDA.

Official Title
-----------------
Patent Ductus Arteriosus Post NICU Discharge in Premature Infants: A Prospective Registry

Conditions
-----------------
Patent Ductus Arteriosus

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Documentation of informed consent and authorization for participation. Estimated gestational age of 32 weeks or less. Active diagnosis of a PDA at discharge. At least one echocardiogram obtained during hospital stay documenting/ confirming PDA diagnosis. Parental agreement to provide follow-up information on their child. Cardiologist and/or Pediatrician willing to provide follow-up information on enrolled infants. Exclusion Criteria: No known major congenital anomalies (inborn error of metabolism, cyanotic congenital heart disease, gastroschisis, omphalocele, diaphragmatic hernia or other major gastrointestinal anomalies, major neurological injury or anomaly, multiple congenital anomalies). Chromosomal / genetic disorders - Inherited metabolic disorders (Aa, fat or carbohydrate), Trisomies, Turner's syndrome,Vater's syndrome, CHARGE, DiGeorge or other 22q11 deletions, Major chromosomal duplications, deletions detectable on high resolution karyotype (not microarray). Parent(s) unwilling to participate in follow-up.

Ages Eligible for Study
-----------------
Minimum Age: 22 Weeks
Maximum Age: 32 Weeks

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of subjects that have a report of a spontaneous closure of PDA, medication intervention for closure of PDA or surgical intervention for closure of PDA |  | 18 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of subjects with or without a closure of PDA that have heart failure, pulmonary arterial hypertension, a need for respiratory support and death |  | 18 months |
The Effect of Prophylactic Hemodialysis on the Morbidity and Mortality of the Patients With Chronic Kidney Disease Stages 3-4 Undergoing Coronary Artery Graft Bypass

Study Overview
=================
Brief Summary
-----------------
Coronary artery disease is a major cause of death in patients with renal dysfunction Among patients who undergo coronary artery bypass grafting ,renal dysfunction is known To be a major predictor of in-hospital and remote mortality As little is known about the impact of non-dialysis-dependent renal dysfunction on short and mid term Outcomes following coronary surgery we have decided to investigate the effect of prophylactic Hemodialysis on the mortality and morbidity of the patients with ckd (stage 3,4 ) and compare these Effect with the control group

Conditions
-----------------
Chronic Kidney Disease stage3, Chronic Kidney Disease stage4, Coronary Artery Disease

Intervention / Treatment
-----------------
* Procedure: hemodialysis


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 80<age>18 ckd patients with stage 3,4 CABG for the first time Exclusion Criteria: age<18 previous CABG (coronary artery bypass grafting) AKI(acute kidney injury) dialysis patients

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: dialysis<br>the patients who undergo 3 sessions prophylactic hemodialysis | Procedure: hemodialysis<br>* 3 sessions hemodialysis before CABG<br>|
| No Intervention: control group<br>the patients who do not undergo hemodialysis | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| morbidity | morbidity is defined as length of hospitalization,infection rate,duration of mechanical ventilation,bleeding complications, | the morbidity during the time of hospitalization until discharge (baseline) and six month later | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| mortality |  | from the time of CABG (baseline) until six months later |